Artemis Medicare Services Receives ₹11.11 Cr GST Show Cause Notice
Artemis Medicare Services Limited received a Show Cause Notice from CGST, Gurugram, for FY 2022-23. The notice alleges non-remittance of GST charged on medicines and consumables to the government, with potential implications of ₹11.11 Crore plus interest and penalty. The company plans to file a writ petition to contest this.
The notice involves a significant financial amount (₹11.11 Crore) and relates to tax compliance, which could impact the company's financials and regulatory standing. However, the company is contesting it with a previous stay order, mitigating the immediate impact.
The company has received a Show Cause Notice with potential financial implications of ₹11.11 Crore, which is a negative development.
Artemis Medicare Services Limited has received a Show Cause Notice dated September 28, 2026, from the Office of the Assistant Commissioner, CGST, Gurugram. This notice pertains to the financial year 2022-23 and alleges that the company charged Goods and Services Tax (GST) on medicines, consumables, and implants supplied to in-patients (IPD) without remitting the same to the government.
The company has stated that the expected financial implications, including potential interest and penalty, amount to ₹11.11 Crore. Artemis Medicare Services Limited had previously filed a writ petition before the Hon’ble High Court of Punjab & Haryana, Chandigarh, concerning a similar Show Cause Notice for an earlier period, for which an interim order staying further proceedings was granted. The company is now in the process of filing another writ before the same High Court to address the current Show Cause Notice and link it with the previous writ petition.
The previous disclosure regarding the earlier writ petition was made on November 22, 2024. The company has affirmed that the information provided in Annexure A is true, correct, and complete to the best of its knowledge and belief.
What to do with a filing like this
Artemis Medicare Services Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Artemis Medicare Services Limited. Read the original for the full detail.